Literature summary for 3.4.21.35 extracted from

Yan, J.T.; Wang, T.; Wang, D.W.
Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects against hypertensive target organ injuries through inhibiting cell apoptosis (2009), Acta Pharmacol. Sin., 30, 1253-1261.

Search for more literature for 3.4.21.35

Application

Application	Comment	Organism
drug development	recombinant adeno-associated virus-mediated tissue kallikrein gene delivery has multiple therapeutic possibilities for treating hypertension, not only by decreasing blood pressure, but also by directly inhibiting end-organ damage	Homo sapiens

Cloned(Commentary)

Cloned (Comment)	Organism
860-bp fragment of tissue kallikrein containing an open reading frame subcloned into pXXUF1 downstream of CMV. recombinant adeno-associated virus encoding tissue kallikrein delivered to spontaneously hypertensive rats and cultured HEK-293 cells	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Synonyms

Synonyms	Comment	Organism
tissue kallikrein	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	treatment with recombinant adeno-associated virus-tissue kallikrein decreases cell apoptosis in the target organs of spontaneous hypertensive rats and also inhibits lipopolysaccharide-induced HEK-293 apoptosis. The recombinant adeno-associated virus-tissue kallikrein delivery system increases the levels of apoptosis-inhibiting proteins bcl-2 and bcl-x(L), and decreases the level of Bax and the activity of caspase 3, two promoters of apoptosis. In addition to its role in the inhibition of apoptosis, adeno-associated virus-tissue kallikrein activates the cell survival and proliferation signaling pathways ERK1/2 and PI3K/AKT	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)